Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ziclor is an ophthalmic gel formulation combining betamethasone, a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, and chloramphenicol, a broad-spectrum antibiotic. Developed by Alfa Intes, Ziclor is approved in Italy for the treatment of non-purulent ophthalmic infections caused by chloramphenicol-sensitive microorganisms when the anti-inflammatory action of a corticosteroid is also required. Its primary indications include inflammation of the anterior segment of the eye (particularly post-operative), bacterial and allergic conjunctivitis, and acute iridocyclitis. The combination provides dual-action therapeutic benefits by reducing ocular swelling, redness, and discomfort while simultaneously treating or preventing bacterial infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on betamethasone + chloramphenicol (Alfa Intes).